Research programme: neurodegenerative disorder stem cell therapy - Cell Cure Neurosciences

Drug Profile

Research programme: neurodegenerative disorder stem cell therapy - Cell Cure Neurosciences

Alternative Names: NeurArrest

Latest Information Update: 22 Aug 2016

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Cell Cure Neurosciences
  • Class Cell therapies
  • Mechanism of Action Cell replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Preclinical Multiple sclerosis; Parkinson's disease

Most Recent Events

  • 15 Aug 2016 BioTime receives patent allowance for Neurodegenerative disorder stem cell therapies in USA, Australia, Canada, China, India, Israel and Japan
  • 26 Jan 2015 BioTime receives patent allowance for its Pluripotent Stem cells in Singapore
  • 23 May 2013 Cell Cure Neurosciences receives grant from the Israeli Ministry of Industry and Commerce to support product development and planned clinical trials
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top